MedPath

Ulinastatin

Generic Name
Ulinastatin
Drug Type
Biotech
CAS Number
80449-31-6
Unique Ingredient Identifier
OR3S9IF86U
Background

Ulinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.

Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

Phase 3
Completed
Conditions
Oral Mucositis (Ulcerative) Due to Radiation
Interventions
Radiation: Intensity Modulated Radiation Therapy
First Posted Date
2018-01-02
Last Posted Date
2025-05-16
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
179
Registration Number
NCT03387774
Locations
🇨🇳

Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China

Ulinastatin Improves Postoperative Oxygenation After Cardiopulmonary Bypass

Phase 4
Completed
Conditions
Cardiac Surgery
Cardiopulmonary Bypass
Interventions
Drug: control
First Posted Date
2017-05-16
Last Posted Date
2017-05-16
Lead Sponsor
Konkuk University Medical Center
Target Recruit Count
80
Registration Number
NCT03154814
Locations
🇰🇷

Konkuk University Medical Center, Seoul, Korea, Republic of

Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)

Not Applicable
Completed
Conditions
Acute Respiratory Distress Syndrome
Critical Illness
Interventions
Other: Usual care
First Posted Date
2017-03-24
Last Posted Date
2024-01-24
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
840
Registration Number
NCT03089957
Locations
🇨🇳

Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China

🇨🇳

Central Hospital of Zi Bo, Zibo, Shandong, China

🇨🇳

CANGZHOU People's Hospital, Cangzhou, Hebei, China

and more 7 locations

The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)

Phase 2
Conditions
Acute Respiratory Distress Syndrome
Interventions
Drug: placebo
First Posted Date
2016-09-09
Last Posted Date
2018-04-20
Lead Sponsor
Techpool Bio-Pharma Co., Ltd.
Target Recruit Count
60
Registration Number
NCT02895191
Locations
🇨🇳

Guangzhou First People's Hospital, Guangzhou, Guangdong, China

🇨🇳

Huadong Hospital,Fudan University, Shanghai, Shanghai, China

🇨🇳

First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 8 locations

Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China

Phase 4
Completed
Conditions
Sepsis
Septic Shock
Interventions
Drug: Placebo
First Posted Date
2016-01-06
Last Posted Date
2022-10-13
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
347
Registration Number
NCT02647554
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery

Phase 4
Conditions
Congenital Heart Diseases
Interventions
First Posted Date
2015-08-19
Last Posted Date
2018-01-17
Lead Sponsor
Techpool Bio-Pharma Co., Ltd.
Target Recruit Count
450
Registration Number
NCT02527811
Locations
🇨🇳

General Hospital of Guangzhou Millitary Command, Guangzhou, Guangdong, China

🇨🇳

Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China

🇨🇳

Shanghai Children's Medical Center, Shanghai, China

and more 2 locations

Post-market Safety Reassessment of Ulinastatin for Injection

Conditions
Adverse Reaction to Drug
Interventions
First Posted Date
2015-08-13
Last Posted Date
2018-04-23
Lead Sponsor
Techpool Bio-Pharma Co., Ltd.
Target Recruit Count
10000
Registration Number
NCT02520570
Locations
🇨🇳

Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China

Effect of Ulinastatin on Postoperative Renal Function in Patients Undergoing Robot-assisted Laparoscopic Partial Nephrectomy

Not Applicable
Completed
Conditions
Renal Mass
Interventions
Drug: normal saline
First Posted Date
2014-10-08
Last Posted Date
2016-08-25
Lead Sponsor
Yonsei University
Target Recruit Count
66
Registration Number
NCT02258906
Locations
🇰🇷

Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection

Not Applicable
Conditions
Acute Aortic Dissection
Interventions
First Posted Date
2013-07-10
Last Posted Date
2014-01-24
Lead Sponsor
Beijing Anzhen Hospital
Target Recruit Count
220
Registration Number
NCT01894334

Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)

Not Applicable
Completed
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2012-07-18
Last Posted Date
2016-03-31
Lead Sponsor
Eastern Hepatobiliary Surgery Hospital
Target Recruit Count
200
Registration Number
NCT01643447
Locations
🇨🇳

Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath